Immunization with fibrillar A[beta]1-42in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain A[beta]

• Published in: Vaccine Vol. 24; no. 15; p. 2824
• Main Authors: Head, Elizabeth, Barrett, Edward G, Murphy, M Paul, Das, Pritam, Nistor, Mihaela, Sarsoza, Floyd, Glabe, Charles C, Kayed, Rakez, Milton, Saskia, Vasilevko, Vitaly, Milgram, Norton W, Agadjanyan, Michael G, Cribbs, David H, Cotman, Carl W
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Limited 05.04.2006
• Subjects: Age; Alzheimer's disease; Animal cognition; Brain; Clinical trials; Dogs; Encephalitis; Hypotheses; Immunization; Laboratory animals; Lymphocytes; Monkeys & apes; Neuropathology; Peptides; Rodents; Studies; Vaccines
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2005.12.058

We describe a study testing fibrillar β-amyloid1-42(Aβ42) vaccination in dogs. Three young beagles (4.6 years) were immunized twice with Aβ42and a Th1 adjuvant (TiterMax Gold). Animals generated primarily IgG2and IgM antibody responses, which were specific for the Aβ11-30region of Aβ1-42. Next, 3 aged beagles (8.9-13.8 years) were immunized 4 times with Aβ42and a Th2 adjuvant (Alum). We observed an acute increase in IgG2,a slower increase in IgG1and Aβ antibodies of broader specificity (Aβ1-15>Aβ11-30>Aβ6-20). A nonsignificant increase in CSF Aβ1-40and decrease in Aβ1-40/1-42in cortex was detected. Canines may be a useful system for testing an Aβ vaccine.